85862-62-0

Basic information

• Product Name: 1-(3-bromophenyl)-1H-1,2,3-triazole
• Synonyms: 1-(3-bromophenyl)-1H-1,2,3-triazole
• CAS NO: 85862-62-0
• Molecular Weight: 224.06
• Mol File: 85862-62-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-(3-bromophenyl)-1H-1,2,3-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-bromophenyl)-1H-1,2,3-triazole(85862-62-0)
• EPA Substance Registry System: 1-(3-bromophenyl)-1H-1,2,3-triazole(85862-62-0)

Safety Data

• Hazardous Substances Data: 85862-62-0(Hazardous Substances Data)

Usage

Chemical class

1-(3-bromophenyl)-1H-1,2,3-triazole belongs to the class of triazoles, which are important building blocks in medicinal and agricultural chemistry.

Structure

The compound is a derivative of 1,2,3-triazole, with a bromine atom attached to the phenyl ring.

Application in coordination chemistry

It is commonly used as a ligand in coordination chemistry.

Use as a precursor

The compound serves as a precursor in the synthesis of various pharmaceuticals and agrochemicals.

Unique structure and reactivity

Its unique structure and reactivity make it a valuable tool in drug discovery and development.

Study of coordination compounds

The compound is useful in the study of coordination compounds and metal-organic frameworks.

Molecular weight

The molecular weight of the compound is approximately 214.05 g/mol.

Appearance

The compound is typically a solid at room temperature.

Solubility

1-(3-bromophenyl)-1H-1,2,3-triazole is likely to be soluble in organic solvents such as dimethyl sulfoxide (DMSO), acetone, or ethanol, but may have limited solubility in water.

Stability

The compound is generally stable under normal laboratory conditions, but should be stored away from light, heat, and moisture to prevent degradation.

Hazards

As with many organic compounds, 1-(3-bromophenyl)-1H-1,2,3-triazole may have potential hazards, such as irritancy or toxicity. It is important to follow proper safety protocols when handling this compound.

Upstream product

• 2101-89-5 1-azido-3-bromobenzene 
• 115-19-5 2-methyl-but-3-yn-2-ol 
• 288-36-8 1,2,3-triazole 
• 108-36-1 1,3-dibromobenzene 
• 1066-26-8 sodium acetylide 
• 74-86-2 acetylene 
• 944905-87-7 C₉H₆BrN₃O₂ 

Downstream Products

• 1428582-07-3 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-1,2,3-triazole 
• 1398744-09-6 4-{[tert-butyl(dimethyl)silyl]oxy}-1-[3-(1H-1,2,3-triazol-1-yl)phenyl]piperidine 

Relevant articles and documents

ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANOMETALLIC COMPOUND FOR THE SAME

The present application relates to an organometallic compound represented by Formula 1 and an organic electroluminescent device, in which the organic electroluminescent device comprises the organometallic compound represented by Formula 1 in an emission l

Discovery of (S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis

A series of 3-aryl(pyrrolidin-1-yl)butanoic acids were synthesized using a diastereoselective route, via a rhodium catalyzed asymmetric 1,4-addition of arylboronic acids in the presence of (R)-BINAP to a crotonate ester to provide the (S) absolute configuration for the major product. A variety of aryl substituents including morpholine, pyrazole, triazole, imidazole, and cyclic ether were screened in cell adhesion assays for affinity against αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins. Numerous analogs with high affinity and selectivity for the αvβ6 integrin were identified. The analog (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt was found to have very high affinity for αvβ6 integrin in a radioligand binding assay (pKi = 11), a long dissociation half-life (7 h), very high solubility in saline at pH 7 (>71 mg/mL), and pharmacokinetic properties commensurate with inhaled dosing by nebulization. It was selected for further clinical investigation as a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis.

NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES

A compound of formula (I) or a salt thereof wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono-or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono-or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H- pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1- yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H- pyrazol-1-yl or 1H- pyrazol-1-yl.